Real-world clinical outcomes in patients with CLL previously treated with covalent BTKi and BCL2i regimens.

Jennifer Prescott¹, Christina M Parrinello², Ahmed Sawas², Enrico De Nigris³, Jing Yang¹, Erik Bloomquist¹, Indu Shrivastava¹, Changxia Shao¹, Xinyue Liu¹, Mohammed Z H Farooqui¹, Sameer A Parikh⁴

¹Merck & Co, Inc, Rahway, NJ.

²Flatiron Health, New York, NY.

³Merck Sharp & Dohme (UK) Limited, London, United Kingdom.

⁴Division of Hematology, Mayo Clinic, Rochester, MN.

PubMed PMC DOI PDF

Abstract

Patients with chronic lymphocytic leukemia (CLL) who are double-exposed (DE) or double-refractory (DR) to covalent Bruton tyrosine kinase inhibitors (cBTKi) and B-cell lymphoma 2 inhibitors (BCL2i) have limited treatment options and poor outcomes. We evaluated real-world treatment patterns, response, and time-to-event (TTE) outcomes in patients with DE CLL (N = 264), and among the DE-only (ie, DE…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.